Correlation Between Type I Interferon Associated Factors and COVID-19 Severity
Overview
Chemistry
Molecular Biology
Authors
Affiliations
Antiviral type I interferons (IFN) produced in the early phase of viral infections effectively inhibit viral replication, prevent virus-mediated tissue damages and promote innate and adaptive immune responses that are all essential to the successful elimination of viruses. As professional type I IFN producing cells, plasmacytoid dendritic cells (pDC) have the ability to rapidly produce waste amounts of type I IFNs. Therefore, their low frequency, dysfunction or decreased capacity to produce type I IFNs might increase the risk of severe viral infections. In accordance with that, declined pDC numbers and delayed or inadequate type I IFN responses could be observed in patients with severe coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as compared to individuals with mild or no symptoms. Thus, besides chronic diseases, all those conditions, which negatively affect the antiviral IFN responses lengthen the list of risk factors for severe COVID-19. In the current review, we would like to briefly discuss the role and dysregulation of pDC/type I IFN axis in COVID-19, and introduce those type I IFN-dependent factors, which account for an increased risk of COVID-19 severity and thus are responsible for the different magnitude of individual immune responses to SARS-CoV-2.
The role of inflammatory gene polymorphisms in severe COVID-19: a review.
Yip J, Oo A, Ng Y, Chin K, Tan K, Chu J Virol J. 2024; 21(1):327.
PMID: 39707400 PMC: 11662554. DOI: 10.1186/s12985-024-02597-3.
Sumichika Y, Temmoku J, Saito K, Yoshida S, Matsumoto H, Watanabe G Intern Med. 2024; 63(10):1491-1498.
PMID: 38369349 PMC: 11157318. DOI: 10.2169/internalmedicine.3211-23.
Overview of anti-viral effects of probiotics via immune cells in pre-, mid- and post-SARS-CoV2 era.
Kanauchi O, Low Z, Jounai K, Tsuji R, AbuBakar S Front Immunol. 2023; 14:1280680.
PMID: 38116008 PMC: 10728489. DOI: 10.3389/fimmu.2023.1280680.
da Fonseca G, Cavalcante L, Brustolini O, Luz P, Pires D, Jalil E Int J Mol Sci. 2023; 24(17).
PMID: 37685953 PMC: 10487928. DOI: 10.3390/ijms241713146.
Renin-Angiotensin System and Sex Differences in COVID-19: A Critical Assessment.
Chappell M Circ Res. 2023; 132(10):1320-1337.
PMID: 37167353 PMC: 10171311. DOI: 10.1161/CIRCRESAHA.123.321883.